Simpsonville, SC – According to filings with the U.S. Securities and Exchange Commission, Elastrin Therapeutics is raising $2,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthias Breugelmans played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elastrin Therapeutics

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

To learn more about Elastrin Therapeutics, visit http://www.elastrin.com/

Contact:
Matthias Breugelmans, Chief Executive Officer
864-650-7155
matthias.breugelmans@elastrin.com
https://www.linkedin.com/in/matthiasbreugelmans/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved